These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33414264)

  • 21. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
    Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
    Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
    J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
    Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
    Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.
    Farrokhpour M; Rezaie N; Moradi N; Ghaffari Rad F; Izadi S; Azimi M; Zamani F; Izadi S; Ranjbar M; Jamshidi Makiani M; Laali A; Roham M; Yadollahzadeh M
    Arch Iran Med; 2021 Feb; 24(2):139-143. PubMed ID: 33636983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
    Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
    Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
    Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
    Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing inpatient care for lung cancer patients with immune checkpoint inhibitor-related pneumonitis using a clinical care pathway algorithm.
    Brito-Dellan N; Franco-Vega MC; Ruiz JI; Lu M; Sahar H; Rajapakse P; Lin HY; Peterson C; Leal-Alviarez D; Altay H; Tomy S; Manzano JM
    Support Care Cancer; 2024 Sep; 32(10):661. PubMed ID: 39283351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
    Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
    Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
    Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
    J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis.
    Lai KA; Sheshadri A; Adrianza AM; Etchegaray M; Balachandran DD; Bashoura L; Shannon VR; Faiz SA
    J Immunother Precis Oncol; 2020 Nov; 3(4):172-174. PubMed ID: 35665375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis.
    Jung J; Kim HY; Kim DG; Park SY; Ko AR; Han JY; Kim HT; Lee JS; Lee Y
    Cancer Res Treat; 2021 Jan; 53(1):77-86. PubMed ID: 32777877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Guo MZ; Balaji A; Murray JC; Reuss JE; Steinke SM; Bennett K; Naidoo J
    Clin Lung Cancer; 2023 Nov; 24(7):613-620. PubMed ID: 37419702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
    Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
    Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.